RT Journal Article
T1 Does there exist an obesity paradox in COVID-19? Insights of the international HOPE-COVID-19-registry.
A1 Abumayyaleh, Mohammad
A1 Núñez Gil, Iván J
A1 El-Battrawy, Ibrahim
A1 Estrada, Vicente
A1 Becerra-Muñoz, Víctor Manuel
A1 Aparisi, Alvaro
A1 Fernández-Rozas, Inmaculada
A1 Feltes, Gisela
A1 Arroyo-Espliguero, Ramón
A1 Trabattoni, Daniela
A1 López-País, Javier
A1 Pepe, Martino
A1 Romero, Rodolfo
A1 García, Diego Raúl Villavicencio
A1 Biole, Carloalberto
A1 Astrua, Thamar Capel
A1 Eid, Charbel Maroun
A1 Alfonso, Emilio
A1 Fernandez-Presa, Lucia
A1 Espejo, Carolina
A1 Buonsenso, Danilo
A1 Raposeiras, Sergio
A1 Fernández, Cristina
A1 Macaya, Carlos
A1 Akin, Ibrahim
A1 HOPE COVID-19 investigators, 
K1 BMI
K1 COVID-19
K1 Obesity paradox
K1 SARS-CoV-2
AB Obesity has been described as a protective factor in cardiovascular and other diseases being expressed as 'obesity paradox'. However, the impact of obesity on clinical outcomes including mortality in COVID-19 has been poorly systematically investigated until now. We aimed to compare clinical outcomes among COVID-19 patients divided into three groups according to the body mass index (BMI). We retrospectively collected data up to May 31st, 2020. 3635 patients were divided into three groups of BMI (30 kg/m2; n = 1061). Demographic, in-hospital complications, and predictors for mortality, respiratory insufficiency, and sepsis were analyzed. The rate of respiratory insufficiency was more recorded in BMI 25-30 kg/m2 as compared to BMI  30 kg/m2 than BMI  30 kg/m2 as compared to BMI  30 kg/m2 as compared to BMI  30 kg/m2 did not impact the mortality rate (HR 1.15, 95% CI: 0.889-1.508; p = 0.27) (HR 1.15, 95% CI: 0.893-1.479; p = 0.27). In multivariate logistic regression analyses for respiratory insufficiency and sepsis, BMI  HOPE COVID-19-Registry revealed no evidence of obesity paradox in patients with COVID-19. However, Obesity was associated with a higher rate of respiratory insufficiency and sepsis but was not determined as an independent predictor for a high mortality.
YR 2021
FD 2021-03-03
LK http://hdl.handle.net/10668/17371
UL http://hdl.handle.net/10668/17371
LA en
DS RISalud
RD Apr 18, 2025